NextGen, Nipro Diagnostics create telemedicine capability monitoring diabetes patients
HORSHAM, Pa. — NextGen Healthcare Information Systems on Wednesday announced a telemedicine agreement with Nipro Diagnostics that would enable users of the company’s NextGen Ambulatory EHR instant access to data points captured by patients at home who are using the Nipro TrueResult blood-glucose monitoring system.
“Home monitoring will become even more important as healthcare providers move toward patient-centered medical home and accountable care organization models,” stated Scott Decker, president of NextGen Healthcare. “Seamlessly integrating data directly from a patient’s meter into NextGen Healthcare’s Ambulatory EHR provides physicians with the necessary tools to better manage the health of their patients with chronic disease while also affording them the ability to reduce hospitalizations and improve quality of life. This allows patients to stay at home healthier and longer before requiring interventions.”
The Nipro Diagnostic Blood Glucose interface imports blood-glucose readings from the TrueResult device into NextGen Healthcare’s Ambulatory EHR, allowing users to view and graph the information captured. The NextGen Nipro Glucose Meter Interface enables electronic downloading of glucose measurements from a Nipro Diagnostics blood-glucose meter into the EHR, automatically populating the appropriate templates and fields, where data can be viewed and analyzed by a physician.
Physicians will gain an immediate benefit from seamlessly performing diagnostic tests with direct entry of information into a patient’s chart, the company stated, eliminating the need to manually re-enter patient data while streamlining processes, reducing data entry errors and increasing efficiencies.
FDA approves Teva biosimilar
JERUSALEM — The Food and Drug Administration has approved a biosimilar drug made by Teva Pharmaceutical Industries for a condition that results from certain chemotherapy treatments, the drug maker said Thursday.
Teva announced the FDA approval of Tbo-filgrastim (XM02 filgrastim) for treating neutropenia, a condition in which the number of white blood cells is decreased, making patients more susceptible to life-threatening bacterial infections. The company sought approval using a biologics license application, or BLA, the same approval pathway used for novel biotech drugs because while the Patient Protection and Affordable Care Act created a regulatory approval pathway for biosimilars, the regulations have not yet been established.
Teva markets filgrastim in Europe under the trade name Tevagrastim, which is a biosimilar version of Amgen’s Neupogen. Teva plans to market tbo-filgrastim starting in November 2013, under an agreement with Amgen.
"As a company dedicated to bringing needed medicines to patients, we are delighted with the approval of tbo-filgrastim, which offers physicians and their patients undergoing chemotherapy a new supportive care treatment option," Teva president of global research and development and chief scientific officer Michael Hayden. "The approval of tbo-filgrastim demonstrates Teva’s strong commitment to providing patients with new treatment options. It expands upon Teva’s existing oncology portfolio with the addition of the first biologic and supportive care agent for oncology patients."
Study: Aspirin regimen could benefit prostate cancer patients
DALLAS — Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday’s issue of the Journal of Clinical Oncology.
The findings demonstrated that 10-year mortality from prostate cancer was significantly lower in a study group taking anticoagulants, compared with a group not taking anticoagulants — 3% as compared with 8%, respectively. The risks of cancer recurrence and bone metastasis also were significantly lower. Further analysis suggested that this benefit was primarily derived from taking aspirin, as opposed to other types of anticoagulants, noted study author Kevin Choe, assistant professor of radiation oncology at UT Southwestern.
The study looked at almost 6,000 men in the Cancer of the Prostate Strategic Urologic Research Endeavor database who had prostate cancer treated with surgery or radiotherapy. About 2,200 of the men involved — 37% — were receiving anticoagulants (warfarin, clopidogrel, enoxaparin and/or aspirin). The risk of death from prostate cancer was compared between those taking anticoagulants and those who were not.
“The results from this study suggest that aspirin prevents the growth of tumor cells in prostate cancer, especially in high-risk prostate cancer, for which we do not have a very good treatment currently,” Choe stated. “But we need to better understand the optimal use of aspirin before routinely recommending it to all prostate cancer patients.”